Overview

* Foghorn Therapeutics ( FHTX ) Q3 collaboration revenue rises, driven by Lilly partnership

* Net loss for Q3 decreases compared to last year

* Company maintains strong cash position with runway into 2028

Outlook

* Foghorn expects selective CBP degrader to be IND-ready in 2026

* Company anticipates IND-enabling studies for EP300 degrader in 2026

* Foghorn projects ARID1B degrader in vivo proof of concept in 2026

Result Drivers

* LILLY COLLABORATION - Ongoing collaboration with Lilly drives advancement of novel oncology medicines, including FHD-909 program

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $8.15

Collabor mln

ation

Revenue

Q3 EPS -$0.25

Q3 Net -$15.84

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Foghorn Therapeutics Inc ( FHTX ) is $11.50, about 69.3% above its November 4 closing price of $3.53

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)